LONG ISLAND, NY — A Long Island resident has filed a lawsuit claiming they lost vision after using popular weight-loss drugs Ozempic and Wegovy, adding to a growing number of legal challenges facing the manufacturer, Novo Nordisk.
The lawsuit alleges that the patient developed a rare eye condition known as non-arteritic anterior ischemic optic neuropathy (NAION), which causes sudden and often permanent vision loss. The legal complaint contends that Novo Nordisk failed to adequately warn patients and healthcare providers about the potential risk of this severe side effect.
Ozempic and Wegovy, both containing the active ingredient semaglutide, have surged in popularity in recent years for their effectiveness in weight loss and managing type 2 diabetes. However, emerging litigation claims that some users have experienced unexpected and serious complications, including vision-related issues.
NAION occurs when blood flow to the optic nerve is reduced, resulting in nerve damage that can lead to partial or complete vision loss. It is a relatively rare condition, but several lawsuits filed across the country suggest a potential link between NAION and semaglutide use. Attorneys argue that this risk should have been disclosed more clearly on drug labels and in marketing materials.
Novo Nordisk has responded to the allegations, stating that NAION is not currently listed as a known side effect of semaglutide in its approved product labeling. The company maintains that the overall safety profile of Ozempic and Wegovy remains favorable based on clinical data and post-market surveillance.
Despite the manufacturer’s position, legal pressure continues to mount. As of May 2025, over 1,800 lawsuits have been filed nationwide against Novo Nordisk and other companies that produce GLP-1 receptor agonists, the class of drugs that includes Ozempic and Wegovy. The cases are being consolidated into a multidistrict litigation (MDL) process in federal court to streamline pretrial proceedings.
The Long Island case adds a local dimension to the broader national debate surrounding the safety of weight-loss medications. The plaintiff’s identity has not been publicly disclosed, and the case is currently pending in state court.
Patients who have experienced sudden vision changes while taking these medications are urged to seek immediate medical attention. Legal experts also advise individuals affected by similar complications to consult with an attorney to understand their rights and potential eligibility for compensation.
